Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

Comprehensively covers the multiplicity and diversity of mechanisms underlying resistance to the currently approved drugs, both tyrosine kinase inhibitors and monoclonal antibodies, that specifically inhibit growth factor receptors playing driver or survival functions in cancerExamines specific targets and the cognate drugsEvaluates molecular modes of innate and evolving resistance

Autorentext
Yosef Yarden, PhD, is Professor, Department of Biological Regulation, The Weizmann Institute of Science, Israel.

Inhalt
Resistance of colorectal tumors to anti-EGFR antibodies.- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK.- Mechanisms of action and resistance of trastuzumab in breast cancer.- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis.- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge.- Mechanisms of resistance to PI3K and AKT inhibitors.- Sensitivity and resistance to BH3 mimetics in cancer therapy.- Resistance mechanisms to cyclin-dependent kinase inhibitors.- Resistance to inhibitors of angiogenesis.